Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects.

Saracaloglu A, Mete AÖ, Ucar DF, Demiryürek S, Erbagcı E, Demiryürek AT

Current protein & peptide science1 Jan 2023Cited by 3 (Europe PMC)

PMID36799414DOI10.2174/1389203724666230217101202PepBankPUB-36799414

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In adults with COVID-19, serum levels of the body's own MOTS‑c were higher than in healthy controls, before and after treatment.
In plain wordsIn adults with COVID-19, the body's own MOTS‑c levels were higher than in healthy people.
Peptide
MOTS-c
Outcome
IncreaseSerum MOTS-c level in COVID-19 versus healthy controls
Study
n = 62
Comparator
Healthy volunteers
Outcome group
Mitochondrial function · Immune and inflammation
Source sentences
Summary
However, we detected a significant augmentation in serum MOTS-c levels when compared to controls (P < 0.01 for pre-treatment and P < 0.001 for post-treatment).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty adult COVID-19 patients and 32 gender-matched healthy volunteers were enrolled in this study.
Summary · context
Circulating humanin and MOTS-c levels were detected using the ELISA method during pretreatment (before drug therapy) and post-treatment (on the 7th day of drug therapy).
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3679941401
02HumanEndogenous levelObservational studyOther
In adults with COVID-19, serum humanin levels were significantly lower than in healthy volunteers.
In plain wordsIn adults with COVID-19, the body's own humanin levels were lower than in healthy volunteers.
Peptide
Humanin
Outcome
DecreaseSerum humanin in COVID-19 patients
Study
n = 62
Comparator
Healthy volunteers
Outcome group
Mitochondrial function · Infection
Source sentences
Summary
We found that there was significant attenuation of the serum humanin levels in COVID-19 patients (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty adult COVID-19 patients and 32 gender-matched healthy volunteers were enrolled in this study.
Summary · context
Circulating humanin and MOTS-c levels were detected using the ELISA method during pretreatment (before drug therapy) and post-treatment (on the 7th day of drug therapy).
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3679941403
03HumanEndogenous levelObservational studyOther
In adults with COVID-19, 7 days of antiviral drug therapy did not change the body's own serum MOTS‑c levels.
In plain wordsIn adults with COVID-19, antiviral drugs did not change the body's own MOTS‑c levels.
Peptide
MOTS-c
Outcome
No significant changeEffect of antiviral drug therapy on serum MOTS-c
Study
n = 30
Comparator
Pre-treatment level
Outcome group
Mitochondrial function · Immune and inflammation
Source sentences
Summary
Interestingly, antiviral drug therapy did not modify the serum MOTS-c and humanin levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Circulating humanin and MOTS-c levels were detected using the ELISA method during pretreatment (before drug therapy) and post-treatment (on the 7th day of drug therapy).
Summary · context
Thirty adult COVID-19 patients and 32 gender-matched healthy volunteers were enrolled in this study.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3679941402
04HumanEndogenous levelObservational studyOther
In adults with COVID-19, antiviral drug therapy for 7 days did not change serum humanin levels.
In plain wordsIn adults with COVID-19, antiviral drugs did not change the body's own humanin levels.
Peptide
Humanin
Outcome
No significant changeSerum humanin after antiviral drug therapy
Study
n = 30
Comparator
Pretreatment
Outcome group
Mitochondrial function · Infection
Source sentences
Summary
Interestingly, antiviral drug therapy did not modify the serum MOTS-c and humanin levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty adult COVID-19 patients and 32 gender-matched healthy volunteers were enrolled in this study.
Summary · context
Circulating humanin and MOTS-c levels were detected using the ELISA method during pretreatment (before drug therapy) and post-treatment (on the 7th day of drug therapy).
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3679941404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 18Current
28 Oct 2026, 02:02 UTC
The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.
Study results updated
Version 3
13 Oct 2026, 16:31 UTC
Study data updated · source update from Europe PMC
Version 2
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.